Genome editing-based therapies typically aim to treat disease by correcting underlying genetic mutations in patient's cells.

INSTALL results showed successful and safe non-viral insertion of large genetic payloads in the livers of mice when delivered by lipid nanoparticles (LNPs). In contrast, mice experienced fatal immune ...

A 19-year-old Chinese woman with a history of systemic lupus erythematous (SLE) visits a rheumatology clinic. She is 24-weeks pregnant and reports ...

Genome editing-based therapies typically aim to treat disease by correcting underlying genetic mutations in patient’s cells. However, most genetic disorders are caused by dozens or even thousands of ...

Genome editing-based therapies typically aim to treat disease by correcting underlying genetic mutations in patient's cells. However, most genetic ...

Objective To evaluate the safety and durability of telitacicept treatment in patients with SLE by identifying the reasons for ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl ...

Ongoing research aims to confirm the mechanism by which ICP4 fluidizes the nucleus, which could indicate specific targets to counter viral replication.

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare subtype of non-Hodgkin lymphoma that frequently presents with multiorgan involvement. We report a diagnostically challenging ...

Objectives Anti-dsDNA antibodies are a hallmark of systemic lupus erythematosus (SLE) and are widely used for diagnosis and disease monitoring. However, discrepancies between screening ELISA assays ...